Sam Fazeli

So what does, and Rush did have some data, which was the Avera, or as I call it, EV era, which is I think what it's meant to be, trial.

How does that, what does that mean for the Serena 4 and the adjuvant Cambria studies?

Just to put again into context, companies are trying to develop

oral versions of drugs that impact the estrogen receptor complex versus what had been used before, which was injections and probably not as well tolerated as it should be.

So do you want to just tell us about that a little bit?

Well, you've answered my next question.

So that's brilliant.

So there is an opportunity to reduce at least ESR1 emergence mutation.

What about if you use this in adjuvants?

Could you, I mean, I know I'm pushing my luck here or at least pushing the luck of biology here.

Could it be possible they can prevent it?

And why is it important for patients not to get ESR1 mutations?

Okay, I think I'll move on to, there's a risk that this ends up being entirely about breast cancer, but there were the two big things, but I really want to cover some bladder before we move on, before we end.

But let's just talk about tropion breast O2 trial.

This is Datraway, TROP2 ADC.

The data, and I'm sure you'll, again, go through the detail a little bit more here,

They just seem better on a response rate basis.

And, you know, this is what we do all our lives, comparing trials, which shouldn't be compared, but there's nothing else we can do.

Otherwise, we wouldn't have a job.

Versus trotelvi in PD-L1 negative, triple negative breast cancer patients.